Cargando…

Multi-Acting Mitochondria-Targeted Platinum(IV) Prodrugs of Kiteplatin with α-Lipoic Acid in the Axial Positions

Platinum(II) drugs are activated intracellularly by aquation of the leaving groups and then bind to DNA, forming DNA adducts capable to activate various signal-transduction pathways. Mostly explored in recent years are Pt(IV) complexes which allow the presence of two additional ligands in the axial...

Descripción completa

Detalles Bibliográficos
Autores principales:	Savino, Salvatore, Marzano, Cristina, Gandin, Valentina, Hoeschele, James D., Natile, Giovanni, Margiotta, Nicola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6073472/ https://www.ncbi.nlm.nih.gov/pubmed/30011897 http://dx.doi.org/10.3390/ijms19072050

Ejemplares similares

Improvement of Kiteplatin Efficacy by a Benzoato Pt(IV) Prodrug Suitable for Oral Administration
por: Barbanente, Alessandra, et al.
Publicado: (2022)

Platinum(IV) Complexes of trans-1,2-diamino-4-cyclohexene: Prodrugs Affording an Oxaliplatin Analogue that Overcomes Cancer Resistance
por: Papadia, Paride, et al.
Publicado: (2020)

Interaction of Copper Trafficking Proteins with the Platinum Anticancer Drug Kiteplatin
por: Barbanente, Alessandra, et al.
Publicado: (2021)

Cisplatin, Oxaliplatin, and Kiteplatin Subcellular Effects Compared in a Plant Model
por: Papadia, Paride, et al.
Publicado: (2017)

Synthesis, Characterization, and Cytotoxicity of the First Oxaliplatin Pt(IV) Derivative Having a TSPO Ligand in the Axial Position
por: Savino, Salvatore, et al.
Publicado: (2016)

A Pt(IV) Prodrug Combining Chlorambucil and Cisplatin: A Dual-Acting Weapon for Targeting DNA in Cancer Cells
por: Montagner, Diego, et al.
Publicado: (2018)

A minimal structural variation can overcome tumour resistance of oxaliplatin: the case of 4,5-dehydrogenation of the cyclohexane ring
por: Papadia, Paride, et al.
Publicado: (2019)

Special Issue “Cisplatin in Cancer Therapy: Molecular Mechanisms of Action 3.0”
por: Gandin, Valentina, et al.
Publicado: (2023)

Potent Chlorambucil-Platinum(IV) Prodrugs
por: Aputen, Angelico D., et al.
Publicado: (2022)

Editorial: The role of platinum-based antitumor prodrugs in medicinal inorganic chemistry
por: Margiotta, Nicola, et al.
Publicado: (2023)

Pt(IV) Prodrugs with NSAIDs as Axial Ligands
por: Spector, Daniil, et al.
Publicado: (2021)

Epigenetic and antitumor effects of platinum(IV)-octanoato conjugates
por: Novohradsky, Vojtech, et al.
Publicado: (2017)

Cell-permeable lanthanide–platinum(iv) anti-cancer prodrugs
por: Yao, Kezi, et al.
Publicado: (2021)

Ligand Evolution in the Photoactivatable Platinum(IV) Anticancer Prodrugs
por: Huang, Jingjing, et al.
Publicado: (2022)

Repurposing Platinum(IV) Prodrugs to Modulate Mitochondrial Metabolism
por: Zacharioudakis, Emmanouil, et al.
Publicado: (2023)

Improving the anticancer activity of platinum(iv) prodrugs using a dual-targeting strategy with a dichloroacetate axial ligand
por: Liu, Fengfan, et al.
Publicado: (2019)

Cyclooxygenase-Inhibiting Platinum(IV) Prodrugs with Potent Anticancer Activity
por: Khoury, Aleen, et al.
Publicado: (2022)

Pt(iv) derivatives of cisplatin and oxaliplatin with phenylbutyrate axial ligands are potent cytotoxic agents that act by several mechanisms of action
por: Raveendran, Raji, et al.
Publicado: (2016)

Tumor-targeted dual-action NSAID-platinum(iv) anticancer prodrugs
por: Kastner, Alexander, et al.
Publicado: (2023)

Oxidative Stress Induced by Pt(IV) Pro-drugs Based on the Cisplatin Scaffold and Indole Carboxylic Acids in Axial Position
por: Tolan, Dina, et al.
Publicado: (2016)

Induction of targeted necrosis with HER2-targeted platinum(iv) anticancer prodrugs
por: Wong, Daniel Yuan Qiang, et al.
Publicado: (2015)

A platinum(IV) prodrug strategy to overcome glutathione-based oxaliplatin resistance
por: Fronik, Philipp, et al.
Publicado: (2022)

Versatile Platinum(IV) Prodrugs of Naproxen and Acemetacin as Chemo-Anti-Inflammatory Agents
por: Aputen, Angelico D., et al.
Publicado: (2023)

Self-assembly nanoplatform of platinum (Ⅳ) prodrug for enhanced ovarian cancer therapy
por: Ma, Xiao, et al.
Publicado: (2023)

Antitumor Trans Platinum DNA Adducts: NMR and HPLC Study of the Interaction Between a trans-Pt Iminoether Complex and the Deoxy Decamer d(CCTCGCTCTC)·d(GAGAGCGAGG)
por: Andersen, Bjørn, et al.
Publicado: (2000)

Axial functionalisation of photoactive diazido platinum(iv) anticancer complexes
por: Shi, Huayun, et al.
Publicado: (2020)

Glutathione boosting the cytotoxicity of a magnetic platinum(iv) nano-prodrug in tumor cells
por: Zhu, Zhenzhu, et al.
Publicado: (2016)

Potent Platinum(IV) Prodrugs That Incorporate a Biotin Moiety to Selectively Target Cancer Cells
por: Khoury, Aleen, et al.
Publicado: (2022)

The impact of whole human blood on the kinetic inertness of platinum(iv) prodrugs – an HPLC-ICP-MS study
por: Theiner, Sarah, et al.
Publicado: (2018)

Oxaliplatin-Based Platinum(IV) Prodrug Bearing Toll-like Receptor 7 Agonist for Enhanced Immunochemotherapy
por: Tang, Li, et al.
Publicado: (2019)

Structure–Activity Relationships of Triple-Action Platinum(IV) Prodrugs with Albumin-Binding Properties and Immunomodulating Ligands
por: Fronik, Philipp, et al.
Publicado: (2021)

pH/redox sensitive nanoparticles with platinum(iv) prodrugs and doxorubicin enhance chemotherapy in ovarian cancer
por: Zhang, Guyu, et al.
Publicado: (2019)

New Oxaliplatin-Pyrophosphato Analogs with Improved In Vitro Cytotoxicity
por: Barbanente, Alessandra, et al.
Publicado: (2021)

Layer-by-layer nanoparticles co-loading gemcitabine and platinum (IV) prodrugs for synergistic combination therapy of lung cancer
por: Zhang, Rongrong, et al.
Publicado: (2017)

Synthesis, Characterization and Biological Investigation of the Platinum(IV) Tolfenamato Prodrug–Resolving Cisplatin-Resistance in Ovarian Carcinoma Cell Lines
por: Barth, Marie-Christin, et al.
Publicado: (2023)

Combination of IDO inhibitors and platinum(IV) prodrugs reverses low immune responses to enhance cancer chemotherapy and immunotherapy for osteosarcoma
por: Xiang, Dongquan, et al.
Publicado: (2023)

In situ oxidative polymerization of platinum(iv) prodrugs in pore-confined spaces of CaCO(3) nanoparticles for cancer chemoimmunotherapy
por: Wei, Fangmian, et al.
Publicado: (2023)

An ultrasound-activatable platinum prodrug for sono-sensitized chemotherapy
por: Liu, Gongyuan, et al.
Publicado: (2023)

“Lantern-Shaped” Platinum(III) Complexes with Axially Bound 9-Ethylguanine or 1-Methylcytosine (L) of General Formula [Pt(2){HN=C(Bu(t))O}(4)L(2)](NO(3))(2)
por: Pacifico, Concetta, et al.
Publicado: (2010)

Albumin-targeting of an oxaliplatin-releasing platinum(iv) prodrug results in pronounced anticancer activity due to endocytotic drug uptake in vivo
por: Schueffl, Hemma, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1g4ec0p5mdgo8seio48umkvq6h